The present invention relates to dual GLP-1 / glucagon receptor agonists, and to medical uses thereof, for example in the treatment of disorders of metabolic syndrome, including diabetes and obesity, as well as for reducing excessive food intake.マルティンボザート...
该研究证明了每周一次的pemvidutide治疗能够显著降低LFC、肝脏炎症活动和体重,这表明pemvidutide可能是治疗MASH和肥胖症的有效方法。 参考文献:Harrison SA, Browne SK, Suschak JJ, et al. Effect of pemvidutide, a GLP-1/glucagon dual receptor ...
会场花絮 原文链接:Lai Wei, Samina Ajaz Hussain, Mandy Fraessdorf, et al. East Asian Sub-Analysis of a Phase 2 Trial of the Glucagon and GLP-1 Receptor Dual Agonist Survodutide in People with Metabolic Dysfunction-As...
GLP-1 medications bind to GLP receptors to trigger the effects (or roles) of the GLP-1 hormone. The higher the dose of the GLP-1 agonist, the more extreme
Opko, Entera share cost of 1st oral GLP-1/glucagon agonist study Mar 17, 2025 10:10am Novo links CagriSema to 16% weight loss, sending stock down Mar 10, 2025 9:30am Ascletis continues obesity surge with competitive GLP-1 data Feb 19, 2025 10:35am Fractyl pivots T2D therapy...
1 Glucagon (胰高血糖素) Glucagon(胰高血糖素)是一种多肽激素,由胰腺的α细胞产生。人类的胰高血糖素glucagon是一个29元多肽,其氨基酸序列为:H-His-Ser-Gln-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Lys-Tyr-Leu-Asp-Ser-Arg-Arg-Ala-Gln-Asp-Phe-Val-Gln-Trp-Leu-Met-Asn-Thr-OH(图1)。
GLP-1R——胰高血糖素样肽-1受体GLP-1(Glucagon-like peptide-1,胰高血糖素样肽-1)是一种由回肠和结肠L细胞分泌的多肽类激素,其受体GLP-1R在胰腺组织中的胰岛β细胞和胃、小肠、心脏、肾脏、肺及大脑等组织中广泛表达。 GLP-1 受体信号通过mTOR依赖性HIF-1α激活促进β细胞葡萄糖代谢[1] 如图所示,GLP-1...
胰高血糖素样肽-1受体(Glucagon-like peptide-1 receptor,GLP-1R),是一种膜上的G蛋白偶联受体(GPCR)。人的GLP-1受体(hGLP-1R)基因位于人染色体6p21。结构上,典型特征是具有一个相对比较大的胞外域(ECD)和有α-螺旋束构成的7次跨膜核心域(TMD)(图1)[1]。该受体的N端胞外段长116个氨基酸残基,含有3对二...
今年,在美国,第一种用于治疗2型糖尿病的双激动剂(dual agonist)药物已被批准上市。这种双激动剂药物结合了GLP-1和GIP(glucose-dependent insulinotropic polypeptide, 葡萄糖依赖性胰岛素多肽)受体激动剂,模拟了肠道激素GLP-1和GIP的作用。 参考资料: Carmelo Quarta et al. GLP-1-mediated delivery of tesaglitazar...
[5]Pelle MC,et al.Role of a Dual Glucose-Dependent Insulinotropic Peptide(GIP)/Glucagon-like Peptide-1 Receptor Agonist(Twincretin)in Glycemic Control:From Pathophysiology to Treatment.Life(Basel).2021 Dec 25;12(1):29. [6]Samms RJ,Coghlan MP,Sloop KW.How may GIP enhance the therapeutic eff...